期刊
ACS APPLIED MATERIALS & INTERFACES
卷 11, 期 1, 页码 176-186出版社
AMER CHEMICAL SOC
DOI: 10.1021/acsami.8b16219
关键词
blood-brain barrier; cediranib; paclitaxel; nanoparticles; bilirubin; glioma
资金
- National Natural Science Foundation of China [81872806, 31571016, 81360162, 81260351]
- Young Elite Scientists Sponsorship Program by CAST [2017QNRC001]
- Sichuan Youth Science and Technology Innovation Research Team Funding [2016TD0001]
- Fundamental of Research Funds for the Central University [SCU2017A001]
The blood brain tumor barrier (BTB) and blood-brain barrier (BBB) have always been the major barriers in glioma therapy. In this report, we proposed D-T7 peptide-modified nanoparticles actively targeted glioma by overcoming the BBB and BTB to improve the antiglioma efficacy. Glioma-targeting experiments showed that the penetration effect of the D-T7 peptide-modified nanoparticles was 7.89-fold higher than that of unmodified nanoparticles. Furthermore, cediranib (CD) and paclitaxel (PTX) were used for the combination of the antiangiogenesis and chemotherapy for glioma. PEGylated bilirubin nanoparticles (BRNPs) were selected as a suitable drug delivery system (CD&PTX@TBRBPs) owing to the antioxidant, anti-inflammatory, and reactive oxygen species-responsive ability. 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) and apoptosis assays showed that CD&PTX@TBRBPs had the highest cytotoxicity and the median survival time of the CD&PTX@TBRNP group was 3.31-fold and 1.23-fold longer than that of the saline and CD&PTX@BRNP groups, respectively. All the results showed that we constructed a novel and accessible peptide-modified dual drug carrier with an enhanced antiglioma effect.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据